Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +14

HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

Erik Laughner, Panthea Taghavi, Kelly A. Chiles et al. · Molecular and Cellular Biology · 2001 · 1.3K citations · Full text

Life Sciences, Cell Biology, Oncology +17

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Véronique Dièras, David Miles, Sunil Verma et al. · The Lancet Oncology · 2017 · 656 citations

Medicine, Oncology, Pharmacology +17

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Ian E. Krop, Nancy U. Lin, Kimberly Blackwell et al. · Annals of Oncology · 2014 · 402 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases

Kevin J. Whitehead, Aubrey C. Chan, Sutip Navankasattusas et al. · Nature Medicine · 2009 · 376 citations

Life Sciences, Molecular Medicine, Neuroscience +16